Spots Global Cancer Trial Database for advanced or metastatic solid tumors
Every month we try and update this database with for advanced or metastatic solid tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) | NCT05382325 | Advanced or Met... | MK-1484 Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors | NCT03616574 | Advanced or Met... Advanced or Met... | CA102N LONSURF | 18 Years - | Holy Stone Healthcare Co., Ltd | |
| A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors | NCT04843709 | Advanced or Met... | MRG004A | 18 Years - | Shanghai Miracogen Inc. | |
| A Study of DF6002 Alone and in Combination With Nivolumab | NCT04423029 | Solid Tumors | DF6002 Nivolumab | 18 Years - | Dragonfly Therapeutics | |
| First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors | NCT03616574 | Advanced or Met... Advanced or Met... | CA102N LONSURF | 18 Years - | Holy Stone Healthcare Co., Ltd | |
| A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors | NCT03316638 | Advanced or Met... | W0101 - Cohort ... W0101 - Cohort ... W0101 - Expansi... | 18 Years - | Pierre Fabre Medicament | |
| Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors | NCT05693844 | Advanced or Met... | Pan-T booster c... Albumin-bound p... Cyclophosphamid... Fludarabine | 18 Years - 75 Years | Chinese PLA General Hospital | |
| A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer | NCT04586270 | Advanced or Met... | TAS0612 | 18 Years - | Taiho Oncology, Inc. | |
| A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors | NCT05388279 | Advanced or Met... | JS012 JS012 combine w... | 18 Years - 70 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| FIH XON7 in Advanced/Metastatic Solid Tumors | NCT06154291 | Advanced Solid ... Metastatic Canc... | XON7 | 18 Years - | Xenothera SAS | |
| Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors | NCT03155061 | Advanced or Met... | ONO-4578 ONO-4538 | 20 Years - | Ono Pharmaceutical Co. Ltd | |
| Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) | NCT04003623 | Advanced or Met... FGFR Mutations FGFR Translocat... | Pemigatinib | 18 Years - | Incyte Corporation | |
| RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors | NCT04252339 | Solid Tumor, Un... | RLY-1971 | 18 Years - | Hoffmann-La Roche | |
| A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors | NCT03316638 | Advanced or Met... | W0101 - Cohort ... W0101 - Cohort ... W0101 - Expansi... | 18 Years - | Pierre Fabre Medicament | |
| A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors | NCT06389526 | Advanced or Met... | CHS-1000 Toripalimab | 18 Years - | Coherus Biosciences, Inc. | |
| A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors | NCT06248411 | Advanced or Met... | KK2260 KK2260 | 18 Years - | Kyowa Kirin Co., Ltd. | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 | NCT05200273 | Advanced or Met... Malignancy Metastasis | AK114 | 18 Years - | Akeso | |
| A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664) | NCT00435669 | Tumors | Brivanib Brivanib | 18 Years - | Bristol-Myers Squibb | |
| A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors | NCT05716295 | Advanced or Met... | MDK-703 Checkpoint Inhi... | 18 Years - 99 Years | Medikine, Inc. | |
| Phase I of XKH002 Injection in Patients | NCT06196762 | Advanced or Met... | XKH002 Injectio... | 18 Years - | Zhejiang Kanova Biopharmaceutical Co., LTD | |
| A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03248843 | Advanced or Met... | KN035 | 20 Years - | 3D Medicines | |
| A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors | NCT05716295 | Advanced or Met... | MDK-703 Checkpoint Inhi... | 18 Years - 99 Years | Medikine, Inc. | |
| A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors | NCT05399654 | Advanced or Met... | TAC-001 | 18 Years - | Tallac Therapeutics | |
| A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors | NCT06248411 | Advanced or Met... | KK2260 KK2260 | 18 Years - | Kyowa Kirin Co., Ltd. | |
| A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors | NCT00907205 | Advanced or Met... Cancer Solid Cancers | SF1126 | 18 Years - | Semafore Pharmaceuticals | |
| A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer | NCT00748553 | Advanced or Met... Advanced or Met... | Azacitidine (Vi... Nab-paclitaxel ... | 18 Years - | University of Utah | |
| A Phase 1 TH-302 Mass Balance Trial | NCT02076230 | Solid Tumor | [14C] TH-302 (L... [14C] TH-302 (L... Unlabeled TH-30... | 18 Years - 70 Years | Merck KGaA, Darmstadt, Germany | |
| A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors | NCT05388279 | Advanced or Met... | JS012 JS012 combine w... | 18 Years - 70 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | NCT03665285 | Advanced or Met... Lung Cancer Breast Cancer Head and Neck S... Endometrial Can... Melanoma CRC Urothelial Carc... Cholangiocarcin... | NC318 | 18 Years - | NextCure, Inc. | |
| A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor | NCT04427774 | Advanced or Met... | Surufatinib plu... | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 | NCT05957081 | Advanced or Met... | PMC-309 monothe... PMC-309 Dose Es... PMC-309 Dose Ex... | 18 Years - | PharmAbcine | |
| A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | NCT04875806 | Advanced or Met... Ovarian Cancer Non-small Cell ... Breast Cancer | NC762 | 18 Years - | NextCure, Inc. | |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations | NCT05907304 | Advanced or Met... | Naporafenib Trametinib | 12 Years - 99 Years | Erasca, Inc. | |
| Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients | NCT05848466 | Advanced or Met... | BAT8010 for Inj... | 18 Years - | Bio-Thera Solutions | |
| Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors | NCT02220049 | Advanced or Met... | Bortezomib | 18 Years - 75 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | NCT05572684 | Advanced or Met... Microsatellite ... Microsatellite ... Microsatellite ... Ovarian Cancer Gastric Cancer Colo-rectal Can... Esophageal Canc... Endometrial Can... Head Neck Cance... Cervical Cancer Lung Cancer | NC410 pembrolizumab | 18 Years - | NextCure, Inc. | |
| A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664) | NCT00437437 | Tumors | Brivanib | 18 Years - | Bristol-Myers Squibb | |
| RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors | NCT04252339 | Solid Tumor, Un... | RLY-1971 | 18 Years - | Hoffmann-La Roche | |
| A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors | NCT05483530 | Advanced or Met... | HLX60 combined ... | 18 Years - | Shanghai Henlius Biotech | |
| Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors | NCT03454243 | Advanced or Met... | RXDX-106 | 18 Years - | Hoffmann-La Roche | |
| RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors | NCT04252339 | Solid Tumor, Un... | RLY-1971 | 18 Years - | Hoffmann-La Roche | |
| A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors | NCT04408599 | Advanced or Met... Ovarian Cancer Gastric Cancer Colo-rectal Can... | NC410 | 18 Years - | NextCure, Inc. | |
| A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) | NCT05382325 | Advanced or Met... | MK-1484 Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase I Clinical Study of Metatinib Tromethamine Tablet | NCT02004548 | Advanced or Met... | Metatinib Trome... | 18 Years - 74 Years | Jiangsu Simcere Pharmaceutical Co., Ltd. | |
| A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer | NCT04586270 | Advanced or Met... | TAS0612 | 18 Years - | Taiho Oncology, Inc. | |
| Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors | NCT05693844 | Advanced or Met... | Pan-T booster c... Albumin-bound p... Cyclophosphamid... Fludarabine | 18 Years - 75 Years | Chinese PLA General Hospital | |
| Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors | NCT01014429 | Advanced or Met... | NMS-1286937 | 18 Years - | Nerviano Medical Sciences | |
| A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors | NCT00276913 | Advanced or Met... | STA-5312 | 18 Years - | Synta Pharmaceuticals Corp. | |
| A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | NCT04875806 | Advanced or Met... Ovarian Cancer Non-small Cell ... Breast Cancer | NC762 | 18 Years - | NextCure, Inc. | |
| A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) | NCT05594043 | Advanced or Met... | MK-6598 Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors | NCT03155061 | Advanced or Met... | ONO-4578 ONO-4538 | 20 Years - | Ono Pharmaceutical Co. Ltd | |
| A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | NCT04381650 | Advanced or Met... | TAK-981 Pembrolizumab | 18 Years - | Takeda | |
| A Phase 1, First-in-Human of KGX101 to Patients With Advanced or Metastatic Solid Tumors | NCT06074497 | Advanced or Met... | KGX101- Cohort ... KGX101- Cohort ... KGX101- Cohort ... KGX101- Cohort ... KGX101- Cohort ... KGX101- Cohort ... KGX101- Cohort ... KGX101- Cohort ... | 18 Years - | Kangabio AUSTRALIA LTD PTY | |
| A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | NCT05753722 | Advanced or Met... | PRTH-101 Pembrolizumab | 18 Years - | Incendia Therapeutics | |
| A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | NCT04381650 | Advanced or Met... | TAK-981 Pembrolizumab | 18 Years - | Takeda | |
| A Phase I Study of TAS-102 in Solid Tumors | NCT02261532 | Advanced or Met... | TAS-102 | 18 Years - 65 Years | Taiho Pharmaceutical Co., Ltd. | |
| Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors | NCT03684785 | Advanced or Met... Advanced or Met... Advanced or Met... Advanced or Met... Advanced or Met... | Cavrotolimod Pembrolizumab Cemiplimab Cavrotolimod | 18 Years - | Exicure, Inc. | |
| Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body | NCT04275960 | Solid Tumors Ha... | Selitrectinib (... | 18 Years - 45 Years | Bayer | |
| A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) | NCT05594043 | Advanced or Met... | MK-6598 Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma | NCT05678998 | Advanced or Met... Non-Hodgkin Lym... | WTX-330 | 18 Years - | Werewolf Therapeutics, Inc. | |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations | NCT05907304 | Advanced or Met... | Naporafenib Trametinib | 12 Years - 99 Years | Erasca, Inc. | |
| A Phase 1, First-in-Human of KGX101 to Patients With Advanced or Metastatic Solid Tumors | NCT06074497 | Advanced or Met... | KGX101- Cohort ... KGX101- Cohort ... KGX101- Cohort ... KGX101- Cohort ... KGX101- Cohort ... KGX101- Cohort ... KGX101- Cohort ... KGX101- Cohort ... | 18 Years - | Kangabio AUSTRALIA LTD PTY | |
| FIH XON7 in Advanced/Metastatic Solid Tumors | NCT06154291 | Advanced Solid ... Metastatic Canc... | XON7 | 18 Years - | Xenothera SAS | |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations | NCT05907304 | Advanced or Met... | Naporafenib Trametinib | 12 Years - 99 Years | Erasca, Inc. | |
| Dose Escalation and Expansion Study of BH3120 in Advanced or Metastatic Solid Tumors | NCT06234397 | Advanced or Met... | BH3120 | 18 Years - | Hanmi Pharmaceutical Company Limited | |
| A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors | NCT03316638 | Advanced or Met... | W0101 - Cohort ... W0101 - Cohort ... W0101 - Expansi... | 18 Years - | Pierre Fabre Medicament | |
| Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors | NCT05598151 | Advanced or Met... | HM97662 | 18 Years - | Hanmi Pharmaceutical Company Limited | |
| Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors | NCT02220049 | Advanced or Met... | Bortezomib | 18 Years - 75 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | NCT01928394 | Advanced or Met... | Nivolumab Ipilimumab Cobimetinib | 18 Years - | Bristol-Myers Squibb | |
| Study of DF6215 in Patients With Advanced Solid Tumors | NCT06108479 | Solid Tumor, Ad... | DF6215 | 18 Years - | Dragonfly Therapeutics | |
| Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 | NCT05957081 | Advanced or Met... | PMC-309 monothe... PMC-309 Dose Es... PMC-309 Dose Ex... | 18 Years - | PharmAbcine | |
| DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | NCT05785754 | Advanced or Met... | DCSZ11 Pembrolizumab | 18 Years - | DynamiCure Biotechnology | |
| A Study of DF6002 Alone and in Combination With Nivolumab | NCT04423029 | Solid Tumors | DF6002 Nivolumab | 18 Years - | Dragonfly Therapeutics | |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | NCT06395519 | Advanced or Met... Breast Cancer Ovarian Cancer Prostate Cancer Epithelial Ovar... BRCA2 Mutation ER+ Breast Canc... Castrate Resist... BRCA1 Mutation BRCA Mutation Endometrial Can... Colorectal Canc... Gastric Cancer | ETX-19477 | 18 Years - | 858 Therapeutics, Inc. | |
| A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03248843 | Advanced or Met... | KN035 | 20 Years - | 3D Medicines | |
| Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors | NCT03454243 | Advanced or Met... | RXDX-106 | 18 Years - | Hoffmann-La Roche | |
| Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors | NCT01014429 | Advanced or Met... | NMS-1286937 | 18 Years - | Nerviano Medical Sciences | |
| To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors | NCT05407909 | Advanced or Met... | SYHX2001 | 18 Years - 75 Years | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors | NCT06374173 | Advanced or Met... | TGI-6 Injection | 18 Years - | Hefei TG ImmunoPharma Co., Ltd. | |
| Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors | NCT03730337 | Advanced or Met... | ONO-7475 ONO-7475 + ONO-... | 20 Years - | Ono Pharmaceutical Co. Ltd |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
